SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-23-122267
Filing Date
2023-04-27
Accepted
2023-04-27 16:25:03
Documents
11
Period of Report
2023-06-06

Document Format Files

Seq Description Document Type Size
1 DEF 14A d415282ddef14a.htm DEF 14A 436364
2 GRAPHIC g415282dsp051a.jpg GRAPHIC 3087
3 GRAPHIC g415282dsp051b.jpg GRAPHIC 1036
4 GRAPHIC g415282dsp051c.jpg GRAPHIC 871
5 GRAPHIC g415282dsp051e.jpg GRAPHIC 1134
6 GRAPHIC g415282dsp051f.jpg GRAPHIC 980
7 GRAPHIC g415282g0414164734243.jpg GRAPHIC 3216
8 GRAPHIC g415282g10n10.jpg GRAPHIC 13119
9 GRAPHIC g415282g49d59.jpg GRAPHIC 1056
10 GRAPHIC g415282g72q29.jpg GRAPHIC 1391
11 GRAPHIC g415282snap1.jpg GRAPHIC 2571
  Complete submission text file 0001193125-23-122267.txt   478035
Mailing Address 427 PARK ST. CHARLOTTESVILLE VA 22902
Business Address 427 PARK ST. CHARLOTTESVILLE VA 22902 925-368-8508
Acumen Pharmaceuticals, Inc. (Filer) CIK: 0001576885 (see all company filings)

IRS No.: 364108129 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40551 | Film No.: 23857391
SIC: 2836 Biological Products, (No Diagnostic Substances)